Search PubMed⌕ Search

Biomedical subjects

K Robinson

Publications and source records attributed to K Robinson.

At least 325 records · Page 18Linked to original sources
PubMedDate not supplied

Restructuring public health in Ontario: implications for heart health promotion.

Community-based heart health promotion is viewed as an effective means of reducing cardiovascular disease risk. Although public health agencies have a central role in the implementation and dissemination of heart health programmes, their effectiveness is being challenged by major structural changes to Provincial public health systems across Canada, although the impacts of the changes have received relatively little attention in the research literature. As part of the Canadian Heart Health Initiative--Ontario Project (CHHIOP), this study used a qualitative approach to address the perceived implications of these changes to Ontario's public health system for heart health promotion. Interviews (n = 38) were conducted in eight public health units with staff most familiar with managing and/or delivering heart health activities. The results are mixed; that is, while many see the future of heart health promotion programming in Ontario as being at risk, others see recent changes as a step forward toward their institutionalization, particularly in light of recent funding decisions made by the Ministry of Health's Health Promotion Branch.

Female↗
PubMedDate not supplied

The effects of lisinopril on serum catecholamine concentrations both at rest and on exercise in patients with congestive cardiac failure. A double blind, placebo controlled, parallel group study.

Patients with congestive cardiac failure have elevated sympathetic activity at rest which contributes to the pathophysiology of this syndrome. In addition, the sympathetic response to exercise in these patients is abnormal. Sympathetic activity is accurately reflected by serum noradrenaline levels. In a double-blind, placebo-controlled, parallel group study, 16 patients of New York Heart Association (NYHA) functional class II, stabilised on optimum doses of diuretics were randomised into two equal groups, to receive either low-dose Lisinopril, an orally active angiotensin converting enzyme (ACE) inhibitor, or matching placebo, over a 12 week period. At the end of the 12 week treatment phase, there was no significant change in noradrenaline levels at rest (p = 0.33) mid exercise (p = 0.17), or peak exercise (p = 0.69), in the lisinopril group. Both lisinopril and placebo groups improved subjectively as assessed by change in NYHA grade, (p < 0.01 for placebo and p < 0.001 for those given lisinopril). Exercise duration improved significantly in the lisinopril group (p = 0.0296), but not in the placebo group after treatment. Low dose lisinopril is of use in congestive cardiac failure even in the absence of measurable changes in sympathetic tone.

Angiotensin-Converting Enzyme Inhibitors↗